US Edition
News from curetoday.com
We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top curetoday.com News
United States · United StatesPhase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoringSee the Story
DARZALEX FASPRO® Is the First and only Treatment Approved by the U.S. FDA for Patients with High-Risk Smoldering Multiple Myeloma
52% Center coverage: 23 sources
United States · United States(MedPage Today) -- The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML).
Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1-mutated...See the Story
Two Drugs Approved for NPM1-Mutated Leukemia
80% Center coverage: 5 sources
Cancer · United States(MedPage Today) -- The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer.
FDA granted the targeted agent an...See the Story
Key HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar
100% Center coverage: 1 sources
